Late complications following renal transplantation;Late complicaties na niertransplantatie

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 23, 2008, Pages 1317-1321

  Bemelman, F J ^a   Ten Benge, R J M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ALLOTRANSPLANTATION; CARDIOVASCULAR DISEASE; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; MORTALITY; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE; REVIEW; RISK FACTOR; TREATMENT FAILURE;

CARDIOVASCULAR DISEASES; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 49649092691     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. ERA-EDTA Registry. ERA-EDTA Registry 2005 annual report. Amsterdam: Academisch Medisch Centrum; 2007.
2. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346:580-90. (Pubitemid 34438820)
3. Baluja P, Haragsim L, Laszik Z. Chronic allograft nephropathy. Adv Chronic Kidney Dis. 2006;13:56-61. (Pubitemid 43075445)
4. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326-33. (Pubitemid 37509740)
5. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation. 2006;81:643-54.
6. Causes of death. USRDS. United States Renal Data System. Am J Kidney Dis. 1997;30(2 Suppl 1):S107-17.
7. Rowshani AT, Scholten EM, Bemelman F, Eikmans M, Idu M, Roosvan Groningen MC, et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporin versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol. 2006;17:305-12.
8. Gelder T van, Hesselink DA, Roodnat JI, IJzermans JN, Weimar W. Niertransplantatie: meer nieren van Ievende donoren, geïndividualiseerde immunosuppressie en betere resultaten. Ned Tijdschr Geneeskd. 2003;147:955-9. (Pubitemid 36604127)
9. Brigand EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med. 2002;347:103-9. (Pubitemid 34753480)
10. Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant. 2006;6:2535-42. (Pubitemid 44571672)
11. Voiculescu A, Schmitz M, Hollenbeck M, Braasch S, Luther B, et al. Management of arterial stenosis affecting kidney graft perfusion. Am J Transplant. 2005;5:1731-8.
12. Berber I, Aydin C, Yigit B, Kara VM, Yildar M, Duzyol C, et al. Blood pressure and graft outcome in renal transplantation. Transplant Proc. 2005;37:997-8. (Pubitemid 40590771)
13. Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant. 2001;16 Suppl 1:121-4. (Pubitemid 32492523)
14. Fernández-Vega F, Tejada F, Baltar J, Laures A, Gómez E, Alvarez J. Ambulatory blood pressure after renal transplantation. Nephrol Dial Transplant. 2001;16 Suppl 1:110-3. (Pubitemid 32492520)
15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease. Am J Kidney Dis. 2002;39(2 Suppl):S1-266.
16. Del Castillo D, Campistol JM, Guirado L, Capdevilla L, Martinez JG, Pereira P, et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl. 1998;68:5135-9.
17. Iñigo P, Campistol JM, Lario S, Piera C, Campos B, Bescós M, et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol. 2001;12:822-7. (Pubitemid 32246711)
18. Kessler M. Cardiovascular disease in terminal end-stage renal failure - epidemiological aspects. Nephrologie. 2002;23:361-5. (Pubitemid 35402949)
19. Hannedouche T, Bouiller M, Caillard S. Absolute cardiovascular risk among nephrology patients. Nephrologie. 1998;19:197-201. (Pubitemid 28294451)
20. Fellström B, Jardine AG, Soveri I, Cole E, Neumayer HH, Maes B, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant. 2005;5:1986-91. (Pubitemid 41039875)
21. Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant. 2001;1 Suppl 2:3-95.
22. Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm jr R, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients. Am J Transplant. 2004:4 Suppl 7:13-53.
23. Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin. Am J Transplant. 2005;5:2929-36. (Pubitemid 43923954)
24. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease. Kidney Int. 2001;59:260-9. (Pubitemid 32055234)
25. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178-85. (Pubitemid 36323115)
26. Fijter JW de. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant. 2007;22 Suppl 1:i23-6.
27. Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation. 2004;77:574-9. (Pubitemid 38282815)
28. Guba M, Lohe F. Transplantation beiTumorerkrankungen-Tumoren nach Organtransplantation. MMW Fortschr Med. 2004;146:32-4. (Pubitemid 38858584)
29. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005;80(2 Suppl):S254-64. (Pubitemid 41552912)
30. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol. 2000;11(Suppl 15):S1-86.
31. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4: 905-13 (Pubitemid 38745589)
32. Fishman JA. Infection in solid-organ recipients. N Engl J Med. 2007;357:2601-14.
33. Ramsey-Goldman R, Dunn JE, Dunlop DD, Stuart FP, Abecassis MM, Kaufman DB, et al. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res. 1999;14:456-63. (Pubitemid 29106723)
34. Zisman AL, Sprague SM. Bone disease after kidney transplantation. Adv Chronic Kidney Dis. 2006;13:35-46. (Pubitemid 43075443)
35. Sprague SM, Josephson MA. Bone disease after kidney transplantation. Semin Nephrol. 2004;24:82-90. (Pubitemid 38141849)
36. Giannini S, d'Angelo A, Carraro G, Antonello A, di Landro D, Marchini F, et al. Persistently increased bone turnover and low bone density in long-term survivors to kidney transplantation. Clin Nephrol. 2001; 56:353-63. (Pubitemid 33041225)
37. Giannini S, d'Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante L, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res. 2001:16:2111-7. (Pubitemid 32995403)
38. Serra AL, Schwarz AA, Wick FH, Marti HP, Wüthrich RP. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005;20:1315-9. (Pubitemid 41430604)